Journal
ADVANCES IN MEDICAL SCIENCES
Volume 65, Issue 2, Pages 348-353Publisher
ELSEVIER URBAN & PARTNER SP Z O O
DOI: 10.1016/j.advms.2020.06.003
Keywords
Children; Inflammatory bowel disease; Crohn's disease treatment; Gut microbiome; qPCR
Categories
Funding
- Jagiellonian University Medical College in Krakow (Poland) [K/ZDS/007042]
Ask authors/readers for more resources
Purpose: The aim of this study was to determine quantitative changes in selected species of bacteria (Bacteroides fragilis, Lactobacillus fermentum, Lactobacillus rhamnosus, Serratia marcescens) in the stool of patients with Crohn's disease (CD) in the course of induction treatment with exclusive enteral nutrition (EEN) or anti-tumor necrosis factor alpha (Infliximab, IFX) vs. healthy controls (HC). Materials/methods: DNA was isolated from stool samples of CD (n = 122) and HC (n = 17), and quantitative real-time Polymerase Chain Reaction (qPCR) was applied. In both treatment groups, the first stool sample was taken before the start of treatment, and the second 4 weeks after its end: in EEN (n = 48; age (mean; SD) 13.35 +/- 3.09 years) and IFX groups (n = 13; age (mean; SD) 13.09 +/- 3.76 years). Results: The only species that showed a statistically significant difference between the two groups of patients before any therapeutic intervention was L. fermentum. Moreover, its number increased after completion of EEN and differed significantly when compared with the HC. In the IFX group the number of L. fermentum decreased during the therapy but was significantly higher than in the HC. The number of S. marcescens in the EEN group was significantly lower than in the controls both before and after EEN. Conclusion: The implemented treatment (EEN or IFX) modifies the microbiome in CD patients, but does not make it become the same as in HC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available